Loading...
Loading...
Piper Jaffray is remaining Neutral on shares of Metabolix
MBLX but is raising its price target to $16 from $13 after the company reported earnings yesterday.
In a note to clients, Piper Jaffray writes, "Bioplastic production continued its measured ramp-up at Metabolix's joint venture facility in 2Q; however, one million cumulative pounds of product sold is not expected until later in the year, which is a couple quarters behind our expectations. Operating results for the quarter were generally in line with our expectations, with a cash burn of $7.4 million. This level of cash burn will likely continue in 2H10. Metabolix continues to make progress on its other crop & chemical platforms. We are lifting our price target to $16 but we are maintaining our Neutral rating."
Shares of Metabolix are being hit hard this morning, trading at $14.48, down $2.01.
Strong Buy Stocks That Have Tripled the Market. See them for free.© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in